NIH to fund DBM CFCL drug discovery program
The grant is expected to support the validation and prioritization of several lead CFCL chemical classes, drugs targeting the most common cystic fibrosis (CF) disease-causing mutation. DBM expects
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.
Thorne Bariatric nutritional product line is made of natural sweeteners and flavorings and is aspartame-free and sucralose-free. The product line includes ImmunoLin, which enhances gastrointestinal and immune health